Humoral immune mechanisms involved in protective and pathological immunity during COVID-19

Autor: Mahnaz Ghaebi, Faroogh Marofi, Gunawan Widjaja, Majid Ahmadi, Heshu Sulaiman Rahman, Walid Kamal Abdelbasset, Jamshid Gholizadeh Navashenaq, Farhad Jadidi-Niaragh, Dmitry Bokov, Abduladheem Turki Jalil, Wanich Suksatan
Rok vydání: 2021
Předmět:
MIP1a
inflammatory protein 1a

medicine.medical_treatment
CoV
coronavirus

G-CSF
Granulocyte colony-stimulating factor

Review
AST
aspartate aminotransferase

2019 novel coronavirus disease (COVID-19)
PHLDA2
Pleckstrin Homology Like Domain Family A Member 2

Pathogenesis
Immunology and Allergy
TNF-α
tumor necrosis factor alpha

CRS
Cytokine release syndrome

MERS-CoV
Middle Eastern Respiratory Syndrome Coronavirus

scRNA-seq
Single-cell RNA sequencing

SOFA
Sequential/Sepsis-related Organ Failure Assessment

General Medicine
ICU
intensive care unit

Hemophagocytic lymphohistiocytosis (HLH)
NK cell
Natural killer cell

Cytokine
Antibody response
Cytokines
medicine.symptom
CAR T cells
Chimeric antigen receptor T cells

IL-1β
interleukin-1β

IP-10
interferon-inducible protein 10

HLH
hemophagocytic lymphohistiocytosis

Immunology
Inflammation
PB
plasmablast

SARS-CoV-2
severe acute respiratory syndrome coronavirus 2

WHO
World Health Organization

MCP1
monocyte chemoattractant protein 1

Lymphohistiocytosis
Hemophagocytic

IFNγ
Interferon gamma

Proinflammatory cytokine
Sepsis
Immune system
Immunity
ACE2
Angiotensin-converting enzyme 2

IgM
Immunoglobulin M

medicine
Animals
Humans
ARDS
acute respiratory distress syndrome

ELISA
enzyme-linked immunoassay

Hemophagocytic lymphohistiocytosis
SARS-CoV-2
business.industry
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
NFIL3
ETS2
nuclear factor regulated by IL-3

COVID-19
2019 novel coronavirus disease

COVID-19
SHLHOS
sepsis-HLH overlap syndrome

medicine.disease
Immunity
Humoral

CCL2
chemokine C–C motif ligand 2

business
Zdroj: Human Immunology
ISSN: 0198-8859
DOI: 10.1016/j.humimm.2021.06.011
Popis: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing COVID-19 is associated with excessive inflammation, as a main reason for severe condition and death. Increased inflammatory cytokines and humoral response to SARS-CoV-2 correlate with COVID-19 immunity and pathogenesis. Importantly, the levels of pro-inflammatory cytokines that increase profoundly in systemic circulation appear as part of the clinical pictures of two overlapping conditions, sepsis and the hemophagocytic syndromes. Both conditions can develop lethal inflammatory responses that lead to tissue damage, however, in many patients hemophagocytic lymphohistiocytosis (HLH) can be differentiated from sepsis. This is a key issue because the life-saving aggressive immunosuppressive treatment, required in the HLH therapy, is absent in sepsis guidelines. This paper aims to describe the pathophysiology and clinical relevance of these distinct entities in the course of COVID-19 that resemble sepsis and further highlights two effector arms of the humoral immune response (inflammatory cytokine and immunoglobulin production) during COVID-19 infection.
Databáze: OpenAIRE